Schizophrenia Research
Volume 116, Issue 1 , Pages 35-43 , January 2010

QTc interval in a sample of long-term schizophrenia inpatients

  • Ramón Ramos-Ríos

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Manuel Arrojo-Romero

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Eduardo Paz-Silva

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Fernando Carballal-Calvo

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • José L. Bouzón-Barreiro

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Jorge Seoane-Prado

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Rosario Codesido-Barcala

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Alicia Crespí-Armenteros

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Ramón Fernández-Pérez

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Javier D. López-Moríñigo

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Ignacio Tortajada-Bonaselt

      Affiliations

    • Department of Psychiatry, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
    • ,
  • Francisco J. Diaz

      Affiliations

    • Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS, United States
    • ,
  • Jose de Leon

      Affiliations

    • Mental Health Research Center at Eastern State Hospital, Lexington, KY, United States
    • Corresponding Author InformationCorresponding author. Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, United States. Tel.: +1 859 246 7563; fax: +1 859 246 7019.

Received 1 August 2009 ,Revised 25 September 2009 ,Accepted 30 September 2009.

References 

  1. Aguilar MC, Gurpegui M, Diaz FJ, de Leon J. Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. Br. J. Psychiatry. 2005;186:215–221
  2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  3. Armas-Barbazán C, López-Moríñigo JD, Ramos-Ríos R, Arrojo-Romero M. Analytic and electrocardiographic abnormalities in schizophrenic patients admitted to an emergency service. Rev. Psiquiatr. Salud. Ment. 2008;1:85–86
  4. Bahaoddini A, Farrashbandi H, Saadat M. Genetic polymorphism of glutathione S-transferase T1 (GSTT1) and QT-interval in schizophrenia patients. J. Mol. Neurosci. 2009;38:173–177
  5. Baldessarini RJ. Chemotherapy in Psychiatry. Cambridge, MA: Harvard University Press; 1985;
  6. Chong SA, Mythily , Lum A, Goh HY, Chan YH. Prolonged QTc intervals in medicated patients with schizophrenia. Hum. Psychopharmacol. 2003;18:647–649
  7. Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, Al Samara M, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog. Cardiovasc. Dis. 2008;51:213–228
  8. Czekalla J, Beasley CM, Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J. Clin. Psychiatry. 2001;62:191–198
  9. de Leon J. Beyond the “hype” on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, and co-morbid substance use (editorial). J. Clin. Psychopharmacol. 2008;28:125–131
  10. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005;76:135–157
  11. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry. 1995;152:453–455
  12. de Leon J, Susce MT, Diaz FJ, Rendon DM, Velasquez DM. Variables associated with alcohol, drug and daily smoking cessation in patients with severe mental illnesses. J. Clin. Psychiatry. 2005;66:1447–1455
  13. de Leon J, Greenlee B, Barber J, Sabaawi M, Singh NN. Practical guidelines for the use of new generation antipsychotics (except clozapine) in adult individuals with developmental disabilities. Res. Dev. Disabil. 2009;30:612–669
  14. Fraguas Herráez D, Laita de Roda P, González Balmaseda G, González Laynez E, Gamo Bravo B, Pascual Hernández D, et al. Factors related to the length of the corrected QT interval in patients treated with antipsychotics. Med. Clin. 2008;130:446–449
  15. Girgis S, Huckstep B, Oakley J, Ferriter M, Nikolaou V. QTc-interval abnormalities in a forensic population. Crim. Behav. Ment. Health. 2007;17:75–88
  16. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. 2001;158:1774–1782
  17. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 2004;24:62–69
  18. Hatta K, Takahashi T, Nakamura H, Yamashiro H, Yonezawa Y. Prolonged QT interval in acute psychotic patients. Psychiatry Res. 2000;94:279–285
  19. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47:264–268
  20. Henderson DC. Schizophrenia and comorbid metabolic disorders. J. Clin. Psychiatry. 2005;66(suppl 6):11–20
  21. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097
  22. Katz A, Grosbard A. Does it all go up in smoke? Cigarette smoking and tachyarrhythmias. J. Cardiovasc. Electrophysiol. 2006;17:937–939
  23. Knoll AG, 1999. Zoleptil (Zotepine) Product Monograph Knoll AG. Knoll AG, Ludwigshafen, Germany.
  24. Koponen H, Alaräisänen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ, et al. Schizophrenia and sudden cardiac death: a review. Nord. J. Psychiatry. 2008;62:342–345
  25. Leotta G, Maule S, Rabbia F, Del Colle S, Tredici M, Canadè A, et al. Relationship between QT interval and cardiovascular risk factors in healthy young subjects. J. Hum. Hypertens. 2005;19:623–627
  26. Lieberman, J.A., Merrill, D., Parameswaran, S., 2009. APA guidance on the use of antipsychotic drugs and cardiac sudden death prepared by for the APA Council on Research. http://www.omh.state.ny.us/omhweb/advisories/adult_antipsychotic_use_attachement.html.
  27. Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J. Clin. Psychiatry. 2005;66:1386–1391
  28. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005;48:215–221
  29. Mangoni AA, Kinirons MT, Swift CG, Jackson SH. Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. Age Ageing. 2003;32:326–331
  30. Manini AF, Raspberry D, Hoffman RS, Nelson LS. QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J. Med. Toxicol. 2007;3:178–181
  31. Matthews D, Hosker J, Rudenski A, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  32. Mencías E, Mayero LM. Manual de Toxicología Básica. Madrid, Spain: Díaz de Santos; 2000;
  33. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev. Neurother. 2007;7:829–839
  34. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006;86:15–22
  35. Novotny T, Florianova A, Ceskova E, Weislamplova M, Palensky V, Tomanova J, et al. Monitoring of QT interval in patients treated with psychotropic drugs. Int. J. Cardiol. 2007;117:329–332
  36. Ozeki Y, Aoki T, Fujii K, Kurimoto N, Takahashi J, Ishida N, et al. Risk factors of QT interval prolongation in Japanese patients with schizophrenia. Int. J. Neuropsychopharmacol. 2008;11:149
  37. Pfizer . GeodonR (ziprasidone HCl), GeodonR (ziprasidone mesylate) for injection for IM use only prescribing information. New York, NY: Pfizer; 2007;
  38. Polselli GM, Cotugno A, Greco S, Ducci G. Antipsychotics and prolongation of the QTc interval: a clinical study. Riv. Psichiatr. 2007;42:327–332
  39. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 2009;360:225–235
  40. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052
  41. Rettenbacher MA, Eder-Ischia U, Bader A, Edlinger M, Hofer A, Hummer M, et al. QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J. Clin. Psychopharmacol. 2005;25:206–210
  42. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int. Clin. Psychopharmacol. 1989;4:95–104
  43. Sala M, Vicentini A, Brambilla P, Montomoli C, Joqia JR, Caverzasi E, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann. Gen. Psychiatry. 2005;4:1
  44. Schillaci G, Pirro M, Ronti T, Gemelli F, Pucci G, Innocente S, et al. Prognostic impact of prolonged ventricular repolarization in hypertension. Arch. Intern. Med. 2006;166:909–913
  45. Schulz P, Rey MJ, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long acting injectable neuroleptics. Int. Clin. Psychopharmacol. 1989;4:105–114
  46. Shin HS, Lee WY, Kim SW, Jung CH, Rhee EJ, Kim BJ, et al. Sex difference in the relationship between insulin resistance and corrected QT interval in non-diabetic subjects. Circ. J. 2005;69:409–413
  47. Singh K. Effect of smoking on QT interval, QT dispersion and rate pressure product. Indian Heart J. 2004;56:140–142
  48. Sumić JC, Barić V, Bilić P, Herceq M, Sisek-Sprem M, Jukić V. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Ann. Gen. Psychiatry. 2007;6:13
  49. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J. Clin. Psychiatry. 2005;66:167–173
  50. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr. Scand. 2003;107:85–95
  51. Vieweg WV. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. J. Clin. Psychiatry. 2002;63(suppl 9):18–24
  52. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br. J. Psychiatry. 1998;173:325–329
  53. Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr. Scand. 1996;93:311–313
  54. Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadish A. Gender differences in arrhythmias. Clin. Cardiol. 2002;25:49–56
  55. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64:663–667
  56. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr. Q. 2003;74:291–306
  57. Ziegler D, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, et al. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp. Clin. Endocrinol. Diabetes. 2006;114:153–159

PII: S0920-9964(09)00485-X

doi: 10.1016/j.schres.2009.09.041

Schizophrenia Research
Volume 116, Issue 1 , Pages 35-43 , January 2010

Article Tools